Curtailing cancer-induced epilepsy
Nature Medicine
September 12, 2011
Blockade of a cystine/glutamate transporter can reduce glioma-induced epilepsy in mice, reports research published online this week in Nature Medicine.
Patients with brain cancers called gliomas often have seizures due to secretion of the excitatory neurotransmitter glutamate from the tumor cells. Gliomas require the amino acid cystine to survive, and the cystine/glutamate transporter on tumor cells shuttles cystine into the tumor cell while simultaneously secreting large amounts of glutamate onto the surrounding brain tissue. This causes neurons in the tumor vicinity to become overexcitable, resulting in the development of seizures.
Harald Sontheimer and colleagues administer a Food and Drug Administration approved inhibitor of the cystine/glutamate transporter called sulfasalazine, which is currently used to treat patients with gut inflammation, to tumor-bearing mice. They show that the drug can prevent the increase in brain glutamate levels caused by the tumors, and can reduce glioma-induced epilepsy in mice. The findings therefore suggest a potential new therapeutic approach to reducing brain tumor-induced seizures in humans.
doi: 10.1038/nm.2453
Research highlights
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
Jun 23
Scientific community: Women credited less than men in scientific paper authorshipNature
-
Jun 17
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
Jun 17
Conservation: Feral cats pushing critically endangered marsupial further towards extinctionScientific Reports
-
Jun 16
Microbiology: DNA analysis indicates origins of the Black DeathNature